Overall (N=202), 85 (64%) rilzabrutinib and 22 (32%) placebo patients achieved platelet response (≥50×109/L or 30× ... risk factors had serious treatment-related grade 3 peripheral embolism (lower ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback